0001179110-18-002253.txt : 20180216
0001179110-18-002253.hdr.sgml : 20180216
20180216160446
ACCESSION NUMBER: 0001179110-18-002253
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180214
FILED AS OF DATE: 20180216
DATE AS OF CHANGE: 20180216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hack Andrew A. F.
CENTRAL INDEX KEY: 0001657434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37687
FILM NUMBER: 18621193
MAIL ADDRESS:
STREET 1: 300 THIRD STREET, FIRST FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Editas Medicine, Inc.
CENTRAL INDEX KEY: 0001650664
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464097528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-401-9000
MAIL ADDRESS:
STREET 1: 11 HURLEY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
edgar.xml
FORM 4 -
X0306
4
2018-02-14
0
0001650664
Editas Medicine, Inc.
EDIT
0001657434
Hack Andrew A. F.
C/O EDITAS MEDICINE, INC.
11 HURLEY ST.
CAMBRIDGE
MA
02141
0
1
0
0
Chief Financial Officer
Common Stock
2018-02-14
4
M
0
6000
6.48
A
6000
D
Common Stock
2018-02-14
4
S
0
6000
32.71
D
0
D
Common Stock
2018-02-15
4
M
0
6000
6.48
A
6000
D
Common Stock
2018-02-15
4
S
0
6000
34.61
D
0
D
Common Stock
2018-02-16
4
M
0
6000
6.48
A
6000
D
Common Stock
2018-02-16
4
S
0
6000
35.32
D
0
D
Stock Option (right to buy)
6.48
2018-02-14
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
75662
D
Stock Option (right to buy)
6.48
2018-02-15
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
69662
D
Stock Option (right to buy)
6.48
2018-02-16
4
M
0
6000
0
D
2025-09-13
Common Stock
6000
63662
D
The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2017.
This transaction was executed in multiple trades at prices ranging from $32.27 to $33.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $34.50 to $34.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $34.82 to $35.79. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This option was granted on September 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.
/s/ Andrew Hack
2018-02-16